START FREE TRIAL

Tesla 2025 EV Deliveries Decline: Europe Turns Its Back on Musk

AI Summary

🔒 UNLOCK AI SUMMARY WITH FREE TRIAL

START FREE TRIAL

Tesla (NASDAQ:TSLA) just reported a bruising end to 2025. Fourth-quarter deliveries came in at 418,227 units—down 16% from the same period last year and shy of Wall Street’s 426,000 estimate. For the full year, deliveries fell 8.6% to 1.64 million vehicles. Production also declined slightly to 434,358 in Q4, suggesting softening demand. What happened? The list is long and telling. The end of the U.S. federal $7,500 EV tax credit on Sept. 30 pulled forward demand into Q3 and left a vacuum in Q4. Meanwhile, Chinese rival BYD overtook Tesla as the world’s top EV seller with 2.26 million units in 2025—nearly 40% more than Tesla. In Europe, the company lost market share amid growing backlash tied to Elon Musk’s political stances and rising competition from names like Volkswagen and Geely. Analysts were mixed: some called the quarter “better than feared,” while others warned of prolonged demand pressures. What does all this mean for 2026?

EV Tax Credit Expiry Gutted U.S. Demand

Let’s start with what hit hardest at home. The U.S. federal government’s $7,500 EV tax credit expired on September 30. Tesla had benefited from this subsidy for…

Continue Reading With Our 7-Day Free Trial

ONLY $10 per month after the trial. Cancel anytime. No sponsors. No conflicts. 100% independent stock research.

Recent Articles

Meta’s AI Launch Looks Like Progress — But Something Feels Off

Meta Platforms (NASDAQ:META) just gave investors a fresh AI...

The “Boring” Healthcare Stock Making A $5 Billion POWER MOVE!

The market loves excitement. But money is often made...

Is Globalstar A Shortcut For Amazon—But A REAL Constraint For Apple?

When a stock jumps on takeover chatter, the easy...

Apple & The AI Supply Crunch — What Wall Street Is Missing!

Apple (NASDAQ:AAPL) is not the company most people think...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

There are biotech stories that look obvious, and then...

Related Articles

Meta’s AI Launch Looks Like Progress — But Something Feels Off

Meta Platforms (NASDAQ:META) just gave investors a fresh AI...

The “Boring” Healthcare Stock Making A $5 Billion POWER MOVE!

The market loves excitement. But money is often made...

Is Globalstar A Shortcut For Amazon—But A REAL Constraint For Apple?

When a stock jumps on takeover chatter, the easy...

Apple & The AI Supply Crunch — What Wall Street Is Missing!

Apple (NASDAQ:AAPL) is not the company most people think...

This AI Infra Stock Could Anchor 6G And Edge Computing; PE Knows It’s MISPRICED!

There’s a reason SBA Communications (NASDAQ: SBAC) has suddenly...

Unilever’s $42 Billion Selloff Is Hiding a Much BIGGER Bet!

Unilever (NYSE: UL) did not just announce a deal—it...

Nike’s China Slump Is Starting to Look Like Something More!

Nike (NYSE:NKE) has spent years selling the idea that...
spot_img

Related Articles

Popular Categories

spot_imgspot_img